Rigel Pharmaceuticals - Best Pharma Stocks of 2007

Company: Rigel Pharmaceuticals
Starting stock price: $11.89
Ending stock price: $25.39
Percent Change: 113.54%

Details: Rigel has a number of drug candidates in its pipeline. R788 is in Phase II trials for rheumatoid arthritis, ITP and B-cell lymphoma. It's also partnering with Merck Serono on the Phase II compound R763 for solid tumors and leukemia. Additionally, Rigel and Pfizer are developing R343 for asthma.

More News:
Merck Serono exercises option to Rigel's R763. Report
Serono seals oncology drug pact with Rigel. Report

Rigel Pharmaceuticals - Best Pharma Stocks of 2007
Read more on

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.